Arzerra, Kesimpta (ofatumumab) is an antibody pharmaceutical. Ofatumumab was first approved as Arzerra on 2009-10-26. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
|Indication||lymphoid leukemia, relapsing-remitting multiple sclerosis|
|Drug Class||Monoclonal antibodies|